Oncotarget

Explore the connection between cellular aging and quiescence in budding yeast, with insights on the influence of geroprotectors like caloric restriction. Discover the role of a complex program in determining yeast cell aging rate and the potential impact on delaying chronological aging. Uncover the new yeast model for studying these mechanisms and the importance of targeting cellular quiescence to delay aging and related diseases.

Researchers Marina Baretti, Qingfeng Zhu, Wei Fu, Jeffrey Meyer, Hao Wang, Robert A. An discuss the synergy between radiotherapy and immune checkpoint inhibitors in rectal cancer. They delve into the impact of neoadjuvant chemoradiotherapy on immune factors, aiming to enhance anti-tumor immune responses and personalized treatment strategies.

Researchers explore the effects of CUDC-907 on NF2 Schwannoma cells, a potential therapy for the rare tumor disorder. The efficacy of CUDC-907 in targeting NF2 Schwannoma cells is discussed, highlighting its multi-pathway targeting capabilities and potential for clinical trials.

Discover how researchers are using machine learning models to predict cancer immunotherapy response based on gut microbiomes. Uncover the importance of gut microbiomes in determining patient responsiveness to immunotherapy and the challenges faced in this field. Explore the potential of statistical models and machine learning in predicting patient outcomes and enhancing cancer responses through understanding microbial interactions.

The podcast discusses how heartburn can lead to esophageal cancer, with a focus on risk factors like smoking and Western diets. It explores the connection between telomere shortening and tumor initiation in Barrett's esophagus, highlighting the potential of telomere dysfunction as a biomarker for predicting cancer risk.

Dr. Robert Hsu discusses the molecular characterization of lung carcinomas expressing KK-LC-1, focusing on the differential expression in adenocarcinoma vs. squamous cell carcinoma, tumor mutational burden, and implications for adoptive cell therapy in non-small cell lung cancer. The podcast also explores KKLC1 expression in lung carcinomas, immune infiltrates, potential cell therapy targeting, collaborations for protein expression evaluation, and drug development efforts.

Discussions center around the role of germline variants in breast cancer metastasis, emphasizing the importance of identifying genetic factors for effective treatment strategies. The impact of genetic makeup on metastasis is explored, including gene dysregulation and germline variants influencing metastatic spread and gene expression patterns.

Researchers discuss the efficacy of continuous treatment with Abemaciclib in inhibiting breast cancer cell proliferation. Abemaciclib shows higher potency than other inhibitors in inhibiting CDK4 kinase activity. It is effective regardless of HER2 status and PI3KCA gene mutation. The impact on myeloid maturation in bone marrow progenitor cells is lower compared to other inhibitors.

Learn about the genetic mutations driving Fusion Positive Rhabdomyosarcoma (FPRMS) and the role of KDM3A and ETS1 in promoting the growth and metastasis of Rhabdomyosarcoma. Discover shared disease-promoting pathways with Ewing's sarcoma and potential therapeutic targets for multiple subtypes.

Explore diverse research papers in Oncotarget Volume 13 focusing on topics like PARP inhibitors, immunotherapy, colorectal cancer, DNA breaks on memory, and nanobiotechnology for targeted therapy. Discover advancements in bladder, breast, and colorectal cancers, genetic influences on cytotoxicity, glucocorticoid receptor therapy for cancer, endometrial cancer cell growth, gene-driven endocrine resistance, treatment combinations for glioblastoma, and immunotherapy responses in specific mutations.